Company / R&D Expense
PLUS THERAPEUTICS, INC. R&D Expense History
FY2011-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$10.6M
FY2025
5-year range
$9.7M / $19.0M
FY2021-FY2025
Trend
+9.2%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
R&D Expense returned to growth in FY2025 after 3 years of decline, reaching $11M.
Based on SEC 10-K filings.
$11M in FY2025 with a 10-year CAGR of -4.7%.
Declined from $12M to $11M over the past 7 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -4.7%
Key checks
Key Insights
- In FY2025, r&d expense increased 9.2% year-over-year.
- Peak r&d expense was recorded in FY2016.
- Lowest r&d expense in the period was in FY2012.
Company context
Key Data Points
- Altman Z-Score -2.46 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $10.6M | +9.2% |
| FY2024 | $9.7M | -17.0% |
| FY2018 | $11.7M | -27.9% |
| FY2017 | $16.2M | -14.8% |
| FY2016 | $19.0M | +11.3% |
| FY2015 | $17.1M | +25.2% |
| FY2014 | $13.6M | +25.0% |
| FY2013 | $10.9M | +12.6% |
| FY2012 | $9.7M | -20.8% |
| FY2011 | $12.2M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026